EUCTR2006-003485-33-GR进行中（未招募）1 期
Duloxetine 60 to 120 mg versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain - HMFG
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Are male or female outpatients at least 40 years of age.
- •- Meet the American College of Rheumatology (ACR) clinical and radiographic criteria for the diagnosis of osteoarthritis (OA) of the knee with pain for greater or equal to 14 days of each month for 3 months prior to study entry.
- •- Have a mean score of 4 or greater on the 24-hour average pain score (0-10).
- •- Are female of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who are not breastfeeding and test negative for pregnancy at Visit 1 or are postmenopausal. Females must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for 1 month following the last dose of the study.
- •- Have an educational level and degree of understanding such that the patient can communicate intelligibly with the investigator and study coordinator.
- •- Are judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol.
- •- Have agreed to maintain the same activity level throughout the course of the study.
- •- Have completed the daily diaries for at least 70% of the days between Visit 1 and Visit 2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family” is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •- Are employed by Lilly (that is, employees, temporary contract workers, or designees responsible for the conduct of the study).
- •- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry (Visit 1).
- •- Have previously completed or withdrawn from this study or any other study investigating duloxetine.
- •- Have had previous exposure to duloxetine.
- •- Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder.
- •- Have major depressive disorder (MDD) as determined using depression module of the Mini International Neuropsychiatric Interview (MINI).
- •- Have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.
- •- Are taking any excluded medications that cannot be discontinued at Visit 1.
- •- Have disability compensation or litigation issues that may compromise response to treatment, in the opinion of the investigator.
- •- Have had treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or the potential need to use an MAOI during the study or within 5 days of discontinuation of study drug.
- •- Have a positive urine drug screen for any substance of abuse or excluded medication.
- •- Are pregnant or breast-feeding.
- •- Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
- •- Have a history of recurrent seizures other than febrile seizures.
- •- Are judged clinically by the investigator to be at suicidal risk or as identified by a score of 2 or greater on question 9 of the Beck Depression Inventory-II (BDI-II) prior to starting study drug.
- •- Have uncontrolled narrow-angle glaucoma.
- •- Have acute liver injury (such as hepatitis) or severe cirrhosis (Child-Pugh Class C).
- •- Have known hypersensitivity to duloxetine or any of the inactive ingredients or patients with frequent or severe allergic reactions to multiple medications.
- •- Have frequent falls that could result in hospitalization or could compromise response to treatment.
- •- Have a confounding painful condition that may interfere with assessment of the index joint, that is, knee. (Knee pain should be the predominant pain. Mild OA of the hands is allowed, for instance.)
- •- Have a diagnosis of inflammatory arthritis (that is, rheumatoid arthritis) or an autoimmune disorder (excluding inactive Hashimoto’s thyroiditis).
- •- Have received intrarticular hyaluronate or steroids, joint lavage, or other invasive therapies to the knee in the past 3 months.
- •- Have had knee arthroscopy of the index knee within the past year or joint replacement of the index knee at anytime.
- •- Have surgery planned during the trial for the index joint.
- •- Has had a prior synovial fluid analysis showing a white blood cell (WBC) greater or equal to 2000 mm3 that is indicative of a diagnosis other than OA.
- •- Are non-ambulatory or require the use of crutches or a walker.
- •- Have a body mass index (BMI) over 40.
研究者
相似试验
进行中（未招募）
1 期
Duloxetine 60 to 120 mg versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain - HMFGOsteoarthritis Knee PainMedDRA version: 8.1Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2006-003485-33-SEEli Lilly and Company Limited230
进行中（未招募）
不适用
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia SyndromeFibromyalgia syndromeMedDRA version: 8.1Level: LLTClassification code 10016631Term: Fibromyalgia syndromeEUCTR2005-001524-37-DEEli Lilly and Company Limited320
进行中（未招募）
1 期
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia SyndromeEUCTR2005-001524-37-GBEli Lilly and Company Limited320
进行中（未招募）
不适用
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndromefibromyalgia syndromeEUCTR2005-001524-37-SEEli Lilly and Company Limited320
进行中（未招募）
1 期
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia SyndromeEUCTR2005-001524-37-ESilly S.A.320